CClinicalTrials.gg
RecruitingNCT06719817ICSIUpdated Dec 6, 2024

Evaluation of Some Trace Elements in Follicular Fluid in ICSI Cases and Their Effect on ICSI Outcomes

An observational study in Good Responders According to Guidelines Who Wre Charectarized by AMH>0.8ng/dl and Trace Elements in ICSI Cases, sponsored by Assiut University. Recruiting at 2 sites in Egypt. Open to female participants aged 25 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
154
Ages
25 Years to 40 Years
Sex
Female
01

Study summary

To evaluate concentrations of some trace elements in the follicular fluid and their reproductive outcomes.

Read the detailed description

To evaluate some trace elements in the follicular fluid and their reproductive outcome

02

Conditions studied

  • Good Responders According to Guidelines Who Wre Charectarized by AMH>0.8ng/dl
  • Trace Elements in ICSI Cases
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4

Eligibility criteria

Inclusion Criteria:good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4 Exclusion Criteria:Poor responders according to ESHRE guidelines as advanced maternal age poor ovarian response and according to NICE guidelines AMH less than 0.8ng/dl

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
154 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. oocyte maturity

    Millimetres

    Time frame: 2024 to 2026

07

Study locations

2 of 2 sites recruiting
  • Faculty of medicine
    Assiut, Egypt
    • Ahmed Nabil Hassan · Contact · 01224532883
    Recruiting
  • Faculty of medicine
    Assiut, Egypt
    • Ahmed Mohammed Nasr, Prof · Contact · 01012588888
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06719817
Lead sponsor
Assiut University
Responsible party
Fatma Ahmed Saad Waley (Doctor, Assiut University) — Principal investigator
First posted
Dec 6, 2024
Start date
Nov 24, 2024
Primary completion
Aug 20, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Dec 6, 2024

Study contacts

Fatma Ahmed Waley
Contact
www.fatma.waley@gmail.com
01064402617
Ahmed Mohammed Nasr
Contact
anasr@edu.eg
01012588888

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion